Navigation Links
Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium
Date:2/13/2008

BRISBANE, Australia, Feb. 13 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced positive preliminary efficacy results from a phase 2 investigator-initiated trial of PI-88 in combination with the chemotherapeutic agent Taxotere(R) (docetaxel) administered to patients with prostate cancer. Dr. Gavin Marx, Royal North Shore Hospital, Sydney Haematology and Oncology Clinics, the principal investigator conducting the trial, will present the preliminary results of the study today at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium in San Francisco.

The investigator-initiated study was a randomized two-arm open-label study design that assessed efficacy and safety of two dose schedules (4 days/week and 7 days/week) of subcutaneous PI-88 in combination with three-weekly Taxotere(R) (75 mg/m2, IV on day 1). The study comprised a lead-in phase 1 safety component to establish the maximum tolerated dose (MTD) of PI-88 at each of the two dosing schedules, followed by a randomized phase 2 component expanding the two dose schedule.

70% of the 55 patients recruited to the trial had a decrease in serum Prostate Specific Antigen (PSA) of greater than 50% for three weeks or longer. These efficacy results compare favourably with the pivotal TAX327 Taxotere(R) registration trial, where 45% of patients had at least a 50% decrease in serum PSA level(1). PSA is a substance produced in the prostate gland, a high level of which may indicate the presence of cancer. In patients with advanced prostate cancer, many clinicians use increasing levels of PSA as an indicator of disease progression.

The trial concluded enrollment early due to a higher-than-expected rate of febrile neutropaenia, a side effect involving a decrease in white blood cells with associated fever. This is a known side effect of Taxotere(R), but was seen in this trial at a substantially greater rate than is generally c
'/>"/>

SOURCE Progen Pharmaceuticals Limited
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
3. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
4. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
5. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
8. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
9. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
10. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
11. A Functional Immune System Can Be Derived From Embryonic Stem Cells, Preliminary Study Finds

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)... , HUNTERSVILLE, N.C., Nov. 30 ... built-in antimicrobial product protection, is ple...tnership with Dal-Tile Corp., the largest U.S. man...ral stone. Dal-Tile Corp is launching two new lin...aturing Microban(®) patent pending silver bas...
(Date:11/30/2009)... , PRINCETON, N.J., Nov. 30 /PRNewswire-FirstCa... that it will present at the Piper Jaffray 21st An... 2, 2009 at 1:30 p.m. (ET). Investors may access ....com . In order to register and download any nece..., Covance, with headquarters in Princeton, New J...
(Date:11/30/2009)... , NEW YORK, Nov. 30 Repo...report is available in its catalogue: ,, Cardi...e Report ,, http://www.reportlinker.com/p0164...telligence-Report.html ,, Cardiovascular dise... globally. Sudden cardiac arrest survivors are pro...
Breaking Medicine Technology:Dal-Tile Corp. Launches Two New Lines of Ceramic Tile with Microban(R) Silver Antimicrobial Technology 2Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report 2Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report 3Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report 4Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report 5Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report 6Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report 7Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report 8IDEXX Laboratories to Release 2009 Second Quarter Financial Results 51842 1AMN Healthcare Names New Chief Financial Officer 51839 1AMN Healthcare Names New Chief Financial Officer 51839 2AMN Healthcare Names New Chief Financial Officer 51839 3Vein Removal Method Linked to Bypass Results 51837 1Vein Removal Method Linked to Bypass Results 51837 2Vein Removal Method Linked to Bypass Results 51837 3
...ugment(TM) to be Featured in July...Pa., June 12 Tengion, Inc., a clinical,stage biot...o-organs and,neo-tissues, announced today that the... with its Neo-Bladder Augment(R) will be featured ...180. The paper, "Early Cellular,and Stromal Respon...
...ters of Sleep Maintenance - - Phas...12 Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) an...ospital presented data from Arena,s positive Phase...insomnia in an oral presentation at the SLEEP,2008...l Sleep Societies in,Baltimore, Maryland., APD125...
Other Medicine Technology:Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair 2Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies 2Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies 3Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies 4Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies 5Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies 6
(Date:12/1/2009)... , NEWPORT BEACH, Calif., Dec. 1 /PRNewswire/ -... that insurers will reimburse them for the $20 cos...for ,going under, for surgery. ,, Anesthesiolog...onitoring is to avoid postop dementia from routine...ts have not heard the ,avoid over-medication, mess...
(Date:12/1/2009)... , SEATTLE, Dec. 1 /PRNewswire-FirstCall/ ...CTIC) management,s presentation at the 21st Annual...December 1 at 11:00 a.m. Eastern Time will be webc...e presentation will take place in Holmes 1 at the ...for replay after the presentation. , , ...
(Date:12/1/2009)...O A study presented today at the annual meeting o... revealed that MRI is a highly accurate means of i...reatening and increasingly common condition that i... and after giving birth. , "Due to the increase...ve scarring on the uterine wall, coupled with wome...
(Date:12/1/2009)...O Results of a randomized, controlled clinical tr...adiological Society of North America (RSNA) reveal...age in arteries that supply blood to the legs and ...silent coronary artery disease. , Peripheral ar...tion of fat, cholesterol and other substances, bui...
(Date:12/1/2009)...rst ever published study of aviation-related injur...013 patients are admitted to U.S. hospitals with a...iation-deaths occur each year. The study, conducte...School of Public Health,s Center for Injury Resear...s that the largest categories of patients were occ...
Breaking Medicine News(10 mins):Health News:5 Shocking Reasons Your Brain Isn't Worth Twenty Bucks Exposed 2Health News:MRI helps detect life-threatening pregnancy complication 2Health News:Severe asymptomatic heart disease may accompany narrowing in leg arteries 2Health News:More than 1,000 patients in US admitted annually for aviation-related injuries 2
...ck Exchange Symbol: CYT, MONTREAL, July 30 /PRNew...a conference call to discuss its third quarter 200... Tuesday, August 5, 2008. The call will be,hosted ... Tuesday, August 5., DATE: Tuesd...
...e highlights that will be presented during the edu...r medical oncology meeting include:, Molecular a...chilles, heel, MicroRNa, SiRNA libraries, Protein...New targets for triple negative tumors, Stem cell ...
... to overwhelming industry interest in new products... Exhibition, VendorClear™ announces that Ven... available for purchase on limited release. , ...[vendor access services] for healthcare facilities...
...ed that it has,signed a new deal with Harro Hoflig...t for the pharmaceutical industry. Harro Hofliger ...stomers minimize risk and,manage quality effective...companies. Among its 400-strong customer base are ...
...ervices,Inc. (NYSE: ACS ) today announced a $4 mi...ds capture for the City of New Orleans Emergency,M... the five-year contract, ACS will equip all New,Or...-time, whether in the field at a patient,s side or...
...oss-border prevention, treatment programs , ...s of HIV infection increase fourfold for male inje... the United States compared to non-deportees in th...est further investigation is necessary into the ri...
Other Medicine News:Health News:CryoCath to Hold Third Quarter 2008 Conference Call and Webcast 2Health News:Get the latest on premier science in medical oncology 2Health News:Get the latest on premier science in medical oncology 3Health News:Get the latest on premier science in medical oncology 4Health News:VendorClear™ Announces Limited Release of New Products for Healthcare Facilities and Vendor Representatives 2Health News:Harro Hofliger Reduces Risk in Pharmaceutical Manufacturing Equipment with Dyadem 2Health News:Harro Hofliger Reduces Risk in Pharmaceutical Manufacturing Equipment with Dyadem 3Health News:ACS Awarded $4 Million Contract to Provide Electronic Patient Records for City of New Orleans EMS 2Health News:Deportation Tied to Higher HIV Risk for Men Injecting Drugs 2Health News:Deportation Tied to Higher HIV Risk for Men Injecting Drugs 3
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
Medicine Products: